Mutual Advisors LLC Has $3.12 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Mutual Advisors LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,393 shares of the biopharmaceutical company’s stock after purchasing an additional 741 shares during the period. Mutual Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,123,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Wendell David Associates Inc. raised its holdings in Bristol-Myers Squibb by 5.2% in the 4th quarter. Wendell David Associates Inc. now owns 20,201 shares of the biopharmaceutical company’s stock valued at $1,143,000 after buying an additional 992 shares during the last quarter. Traynor Capital Management Inc. raised its stake in shares of Bristol-Myers Squibb by 4.3% during the fourth quarter. Traynor Capital Management Inc. now owns 7,275 shares of the biopharmaceutical company’s stock valued at $411,000 after acquiring an additional 300 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Bristol-Myers Squibb by 29.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 954,727 shares of the biopharmaceutical company’s stock worth $53,999,000 after purchasing an additional 217,603 shares during the period. Magnus Financial Group LLC grew its stake in shares of Bristol-Myers Squibb by 28.4% in the fourth quarter. Magnus Financial Group LLC now owns 7,814 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 1,727 shares during the last quarter. Finally, Daymark Wealth Partners LLC increased its holdings in Bristol-Myers Squibb by 0.8% in the fourth quarter. Daymark Wealth Partners LLC now owns 77,964 shares of the biopharmaceutical company’s stock valued at $4,410,000 after purchasing an additional 614 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $59.15 on Friday. The stock has a market cap of $119.97 billion, a P/E ratio of -16.48, a P/E/G ratio of 2.02 and a beta of 0.45. The business’s fifty day moving average is $57.39 and its 200 day moving average is $52.36. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period last year, the company earned $2.00 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. Sell-side analysts anticipate that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The stock was purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on BMY. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. UBS Group increased their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Citigroup increased their price objective on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. Finally, Morgan Stanley upped their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $56.27.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.